Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeSurgical Skin Prep Solution3M SoluPrep Film-Forming Sterile Surgical Solution an Advanced Surgical Skin Prep Solution...

3M SoluPrep Film-Forming Sterile Surgical Solution an Advanced Surgical Skin Prep Solution Aiding in Patient Infection Prevention


Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets –

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts –

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

October 9, 2018

3M SoluPrep Film-Forming Sterile Surgical Solution is a 2% chlorhexidine gluconate and 70% isopropyl alcohol surgical skin prep that uses 3M technology to help clinicians in the fight against SSIs.

As a surgeon, I know there is always a risk to the patient of acquiring a surgical site infection,” said Dr. Daniel Segina, orthopedic trauma surgeon with Health First, Holmes Regional Medical Center. “New technologies are welcomed as an opportunity for us to better care for our patients and reduce potential complications associated with surgery.”

The new product leverages 3M’s expertise in polymer and adhesive technology in the form of a proprietary 3M™ Prep Protection Film. When the copolymer film dries, it forms a water-insoluable film on the skin, helping the proven bacteria-killing agent chlorhexidine gluconate (CHG) stay on a patient’s skin and able to withstand the rigors of simulated surgical conditions – including repetitive wiping.

“At 3M, we apply 3M Science to deliver safe and effective solutions that help improve patients’ lives and outcomes,” said Dr. Todd Fruchterman, vice president and general manager, 3M Medical Solutions Division. “While we are always looking for ways to arm our clinicians with the most advanced infection prevention solutions possible, we also encourage patients to help take control of their own outcomes by asking their care team about surgical preps and learning how they can help protect them.”

In studies comparing 3M SoluPrep Film-Forming Sterile Surgical Solution to the current market-leading CHG prep, the 3M solution was shown to have:

  • More CHG remaining on the skin after subjection to simulated surgical conditions2,3*
  • Easy visibility on all skin tones to help track coverage and make sure no spots are missed4,5
  • High viscosity to minimize running6, which can lead to dripping and pooling—a known operating room fire and patient chemical burn risk.


1) Center for Disease Control and Prevention:
2) Data on file. 3M Study EM-05-013603, 3M Health Care.
3) Data on file. TECH-REPORT-05-299473, 3M Health Care.
4) Data on file. 3M Study EM-05-014116, 3M Health Care.
5) Data on file. 3M Study EM-05-014182, 3M Health Care.
6) Data on file. TECH-REPORT-05-302302, 3M Health Care.

*Using an ex vivo porcine skin model, equivalently sized areas were prepped with SoluPrep™ Film-Forming Sterile Surgical Solution and the current market-leading prep and challenged with repetitive saline soak/wipe.



AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy